Florian Krismer
Overview
Explore the profile of Florian Krismer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
2821
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cerejo C, De Cleene N, Mandler E, Schwarzova K, Labrecque S, Mahlknecht P, et al.
Neurol Int
. 2025 Jan;
17(1.
PMID: 39852777
Huntington's disease (HD) is a progressive neurodegenerative disorder for which, until now, only symptomatic treatment has been available. Lately, there have been multiple ongoing clinical trials targeting therapeutic agents for...
2.
Fanciulli A, Sixel-Doring F, Buhmann C, Krismer F, Hermann W, Winkler C, et al.
J Neurol
. 2025 Jan;
272(1):90.
PMID: 39751950
Background And Objective: Non-motor symptoms frequently develop throughout the disease course of Parkinson's disease (PD), and pose affected individuals at risk of complications, more rapid disease progression and poorer quality...
3.
Krismer F, Fanciulli A, Meissner W, Coon E, Wenning G
Lancet Neurol
. 2024 Nov;
23(12):1252-1266.
PMID: 39577925
Multiple system atrophy is an adult-onset, sporadic, and progressive neurodegenerative disease. People with this disorder report a wide range of motor and non-motor symptoms. Overlap in the clinical presentation of...
4.
Breitegger C, Krismer F, Lorenzl S, Schrag A, Jahn B, Knoflach-Gabis A, et al.
Clin Auton Res
. 2024 Jul;
34(3):321-326.
PMID: 38965149
No abstract available.
5.
Theyer C, Beliveau V, Krismer F, Peball M, Mair K, Heim B, et al.
Mov Disord Clin Pract
. 2024 May;
11(7):855-860.
PMID: 38715209
Background: Subthalamic deep brain stimulation (STN-DBS) reduces antiparkinsonian medications in Parkinson's disease (PD) compared with the preoperative state. Longitudinal and comparative studies on this effect are lacking. Objective: To compare...
6.
Chia R, Ray A, Shah Z, Ding J, Ruffo P, Fujita M, et al.
Neuron
. 2024 May;
112(13):2142-2156.e5.
PMID: 38701790
Multiple system atrophy (MSA) is an adult-onset, sporadic synucleinopathy characterized by parkinsonism, cerebellar ataxia, and dysautonomia. The genetic architecture of MSA is poorly understood, and treatments are limited to supportive...
7.
Fanciulli A, Stankovic I, Avraham O, Lukic M, Ezra A, Leys F, et al.
Mov Disord Clin Pract
. 2024 Apr;
PMID: 38659282
Background: A 4-item score based on ≥2 features out of orthostatic hypotension, overactive bladder, urinary retention and postural instability was previously shown to early distinguish the Parkinson-variant of multiple system...
8.
Leys F, Eschlbock S, Campese N, Mahlknecht P, Peball M, Goebel G, et al.
Clin Auton Res
. 2024 Apr;
34(2):253-268.
PMID: 38630378
Purpose: To investigate sex-related differences in the clinical presentation of multiple system atrophy (MSA) through a literature review and an analysis of a retrospective cohort. Methods: The PubMed database was...
9.
Heim B, Mandler E, Buchmann A, Grossauer A, Peball M, Valent D, et al.
Mov Disord Clin Pract
. 2024 Mar;
11(7):912-913.
PMID: 38533634
No abstract available.
10.
Peball M, Heim B, Carbone F, Schorr O, Werkmann M, Ellmerer P, et al.
NPJ Parkinsons Dis
. 2024 Mar;
10(1):61.
PMID: 38491070
The synthetic tetrahydrocannabinol-analog nabilone improved non-motor symptoms (NMS) in Parkinson's disease (PD) patients in a placebo-controlled, double-blind, parallel-group, randomized withdrawal trial with enriched enrollment (NMS-Nab-study). This was a single-center open-label...